283 related articles for article (PubMed ID: 31641627)
1. Prospective Study of Bethesda Categories III and IV Thyroid Nodules: Outcomes and Predictive Value of BRAF
Chirayath SR; Pavithran PV; Abraham N; Nair V; Bhavani N; Kumar H; Menon UV; Menon AS
Indian J Endocrinol Metab; 2019; 23(3):278-281. PubMed ID: 31641627
[TBL] [Abstract][Full Text] [Related]
2.
Zhu Y; Wu H; Huang B; Shen X; Cai G; Gu X
Gland Surg; 2020 Oct; 9(5):1674-1684. PubMed ID: 33224845
[TBL] [Abstract][Full Text] [Related]
3. Malignancy rate in thyroid nodules classified as Bethesda category III (AUS/FLUS).
Ho AS; Sarti EE; Jain KS; Wang H; Nixon IJ; Shaha AR; Shah JP; Kraus DH; Ghossein R; Fish SA; Wong RJ; Lin O; Morris LG
Thyroid; 2014 May; 24(5):832-9. PubMed ID: 24341462
[TBL] [Abstract][Full Text] [Related]
4. Clinico-cytopathological subcategorization in thyroid nodules of atypia of undetermined significance/follicular lesion of undetermined significance using the TIRADS and Bethesda classifications.
Babajani A; Rahmani S; Raoufi M; Eidgahi ES; Dastjerdi AV; Behfarnia P; Khalili S; Moghaddam NA
Front Endocrinol (Lausanne); 2023; 14():1135196. PubMed ID: 37313444
[TBL] [Abstract][Full Text] [Related]
5. Subclassification of Bethesda Atypical and Follicular Neoplasm Categories According to Nuclear and Architectural Atypia Improves Discrimination of Thyroid Malignancy Risk.
Lim JXY; Nga ME; Chan DKH; Tan WB; Parameswaran R; Ngiam KY
Thyroid; 2018 Apr; 28(4):511-521. PubMed ID: 29596039
[TBL] [Abstract][Full Text] [Related]
6. The prediction of malignant risk in the category "atypia of undetermined significance/follicular lesion of undetermined significance" of the Bethesda System for Reporting Thyroid Cytopathology using subcategorization and BRAF mutation results.
Hyeon J; Ahn S; Shin JH; Oh YL
Cancer Cytopathol; 2014 May; 122(5):368-76. PubMed ID: 24591408
[TBL] [Abstract][Full Text] [Related]
7. Combining molecular testing and the Bethesda category III:VI ratio for thyroid fine-needle aspirates: A quality-assurance metric for evaluating diagnostic performance in a cytopathology laboratory.
Gokozan HN; Dilcher TL; Alperstein SA; Qiu Y; Mostyka M; Scognamiglio T; Solomon JP; Song W; Rennert H; Beg S; Stern E; Goyal A; Siddiqui MT; Heymann JJ
Cancer Cytopathol; 2022 Apr; 130(4):259-274. PubMed ID: 34962713
[TBL] [Abstract][Full Text] [Related]
8. Patient outcomes following surgical management of thyroid nodules classified as Bethesda category III (AUS/FLUS).
Mulita F; Plachouri MK; Liolis E; Vailas M; Panagopoulos K; Maroulis I
Endokrynol Pol; 2021; 72(2):143-144. PubMed ID: 33749812
[TBL] [Abstract][Full Text] [Related]
9. ACR TI-RADS and ATA US scores are helpful for the management of thyroid nodules with indeterminate cytology.
Barbosa TLM; Junior COM; Graf H; Cavalvanti T; Trippia MA; da Silveira Ugino RT; de Oliveira GL; Granella VH; de Carvalho GA
BMC Endocr Disord; 2019 Oct; 19(1):112. PubMed ID: 31664992
[TBL] [Abstract][Full Text] [Related]
10. The Risk Stratification of Papillary Thyroid Cancer With Bethesda Category III (Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance) by Thyroid Fine-Needle Aspiration Could Be Assisted by Tumor Size for Precision Treatment.
Zha X; Miao Z; Huang X; Wang X; Xie R; Jin J; Zou D; Yang P; Huang Y
Front Endocrinol (Lausanne); 2022; 13():822423. PubMed ID: 35197932
[TBL] [Abstract][Full Text] [Related]
11. Risk of malignancy according to sub-classification of the atypia of undetermined significance or follicular lesion of undetermined significance (AUS/FLUS) category in the Bethesda system for reporting thyroid cytopathology.
Kim SJ; Roh J; Baek JH; Hong SJ; Shong YK; Kim WB; Song DE
Cytopathology; 2017 Feb; 28(1):65-73. PubMed ID: 27245883
[TBL] [Abstract][Full Text] [Related]
12. Thyroid nodules with atypia or follicular lesions of undetermined significance (Bethesda Category III): importance of ultrasonography and cytological subcategory.
Rosario PW
Thyroid; 2014 Jul; 24(7):1115-20. PubMed ID: 24684285
[TBL] [Abstract][Full Text] [Related]
13. ThyroSeq v3 for Bethesda III and IV: An institutional experience.
Desai D; Lepe M; Baloch ZW; Mandel SJ
Cancer Cytopathol; 2021 Feb; 129(2):164-170. PubMed ID: 33030808
[TBL] [Abstract][Full Text] [Related]
14. Cancer rate of Bethesda category II thyroid nodules.
Mulita F; Iliopoulos F; Tsilivigkos C; Tchabashvili L; Liolis E; Kaplanis C; Perdikaris I; Maroulis I
Med Glas (Zenica); 2022 Feb; 19(1):. PubMed ID: 34734516
[TBL] [Abstract][Full Text] [Related]
15. UTILITY OF AFIRMA GENE EXPRESSION CLASSIFIER FOR EVALUATION OF INDETERMINATE THYROID NODULES AND CORRELATION WITH ULTRASOUND RISK ASSESSMENT: SINGLE INSTITUTIONAL EXPERIENCE.
Sultan R; Levy S; Sulanc E; Honasoge M; Rao SD
Endocr Pract; 2020 May; 26(5):543-551. PubMed ID: 31968199
[No Abstract] [Full Text] [Related]
16. BRAF V600E mutation and the Bethesda System for Reporting Thyroid Cytopathology of fine-needle aspiration biopsy for distinguishing benign from malignant thyroid nodules.
Sheng D; Yu X; Li H; Zhang M; Chen J
Medicine (Baltimore); 2021 Sep; 100(37):e27167. PubMed ID: 34664843
[TBL] [Abstract][Full Text] [Related]
17. Thyroid cytology-nuclear versus architectural atypia within the "Atypia of undetermined significance/follicular lesion of undetermined significance" Bethesda category have significantly different rates of malignancy.
Gan TR; Nga ME; Lum JH; Wong WM; Tan WB; Parameswaran R; Ngiam KY
Cancer Cytopathol; 2017 Apr; 125(4):245-256. PubMed ID: 28192631
[TBL] [Abstract][Full Text] [Related]
18. Risk of Malignancy and Risk of Neoplasia in the Bethesda Indeterminate Categories: Study on 4,532 Thyroid Fine-Needle Aspirations from a Single Institution in India.
Mahajan S; Srinivasan R; Rajwanshi A; Radotra B; Panda N; Dey P; Gupta N; Nijhawan R
Acta Cytol; 2017; 61(2):103-110. PubMed ID: 28407624
[TBL] [Abstract][Full Text] [Related]
19. Impact of reclassifying noninvasive follicular variant of papillary thyroid carcinoma on the risk of malignancy in The Bethesda System for Reporting Thyroid Cytopathology.
Faquin WC; Wong LQ; Afrogheh AH; Ali SZ; Bishop JA; Bongiovanni M; Pusztaszeri MP; VandenBussche CJ; Gourmaud J; Vaickus LJ; Baloch ZW
Cancer Cytopathol; 2016 Mar; 124(3):181-7. PubMed ID: 26457584
[TBL] [Abstract][Full Text] [Related]
20. CLINICAL IMPACT OF NON-INVASIVE FOLLICULAR THYROID NEOPLASM WITH PAPILLARY-LIKE NUCLEAR FEATURES ON THE RISK OF MALIGNANCY IN THE BETHESDA SYSTEM FOR REPORTING THYROID CYTOPATHOLOGY: A META-ANALYSIS OF 14,153 RESECTED THYROID NODULES.
Vuong HG; Tran TTK; Bychkov A; Jung CK; Nakazawa T; Kakudo K; Katoh R; Kondo T
Endocr Pract; 2019 May; 25(5):491-502. PubMed ID: 30657357
[No Abstract] [Full Text] [Related]
[Next] [New Search]
